Disulfidptosis related immune genes drive prognostic model development and tumor microenvironment characterization in bladder urothelial carcinoma

Mar 8, 2025Scientific reports

Immune genes linked to disulfidptosis help predict outcomes and describe the tumor environment in bladder cancer

AI simplified

Abstract

RNA-seq data from 419 patients identified eight immune genes linked to bladder urothelial carcinoma prognosis.

  • is associated with bladder urothelial carcinoma progression and treatment outcomes.
  • A disulfidptosis-related immune risk scoring system was developed to enhance treatment strategies.
  • Patients with low-risk scores demonstrated higher overall survival rates and than high-risk patients.
  • Immune cell types, including CD4 memory T cells and CD8 T cells, were more prevalent in the low-risk group.
  • The high-risk score group showed a stronger correlation with cancer malignant pathways.
  • The TNFRSF12A gene was identified as an oncogene in bladder urothelial carcinoma.

AI simplified

Key numbers

90%
Overall Survival Rate
Approximately 90% of non-muscle-invasive BLCA patients survive over five years.
0.748
Risk Score Prediction Accuracy
AUC for predicting one-year survival rates based on risk scores.
0.0067
Comparison
Statistical significance of differences between low-risk and high-risk groups.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free